Hepatoma Research

Scope & Guideline

Elevating the Standard of Hepatology and Oncology

Introduction

Delve into the academic richness of Hepatoma Research with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN2394-5079
PublisherOAE PUBLISHING INC
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 2019 to 2024
AbbreviationHEPATOMA RES / Hepatoma Res.
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address245 E MAIN ST, ST122, ALHAMBRA, CA 91801

Aims and Scopes

Hepatoma Research is dedicated to advancing the understanding and treatment of liver cancers, particularly hepatocellular carcinoma (HCC) and cholangiocarcinoma. The journal emphasizes innovative research methodologies that span clinical, translational, and basic science, aiming to improve patient outcomes and treatment modalities.
  1. Hepatocellular Carcinoma (HCC) Research:
    The journal focuses extensively on various aspects of HCC, including its risk factors, molecular mechanisms, treatment strategies, and outcomes, thereby contributing to a better understanding of this prevalent liver cancer.
  2. Cholangiocarcinoma Studies:
    Cholangiocarcinoma, another critical area of focus, is explored through studies that cover its epidemiology, molecular pathology, and treatment advancements, highlighting the need for improved management strategies.
  3. Innovative Treatment Modalities:
    There is a consistent emphasis on novel treatment approaches, including minimally invasive surgeries, radiation therapies, and the use of immunotherapy and targeted therapies, reflecting the journal's commitment to advancing clinical practice.
  4. Multidisciplinary Approaches:
    The journal promotes multidisciplinary research and treatment approaches, integrating perspectives from surgery, oncology, radiology, and pathology to provide comprehensive care for liver cancer patients.
  5. Patient-Centric Research:
    Hepatoma Research also prioritizes research that addresses patient perspectives, quality of life, and real-world outcomes, fostering a holistic understanding of treatment impacts.
The journal has shown a dynamic evolution in its research focus, with several emerging themes gaining significant attention in recent publications. These trends reflect the ongoing advancements in understanding liver cancer and the pursuit of innovative treatment strategies.
  1. Immunotherapy and Checkpoint Inhibitors:
    Recent publications highlight the growing interest in immunotherapy, particularly immune checkpoint inhibitors, as promising treatment options for HCC, reflecting a shift towards harnessing the immune system in cancer treatment.
  2. Minimally Invasive Surgical Techniques:
    There is an increasing trend in research dedicated to minimally invasive surgical techniques for liver cancer treatment, indicating a broader acceptance and application of these approaches in clinical practice.
  3. Molecular and Genetic Profiling:
    Emerging studies focus on the molecular and genetic profiling of liver cancers, which is crucial for the development of personalized medicine strategies and targeted therapies.
  4. Microbiome and Liver Health:
    Recent articles explore the relationship between the gut microbiome and liver diseases, signaling an emerging interest in how microbial health impacts liver cancer development and progression.
  5. Real-World Data and Patient Outcomes:
    An emphasis on real-world data analysis and patient outcomes has emerged, reflecting a growing interest in understanding the effectiveness and impact of treatments in diverse populations.

Declining or Waning

As the field of liver cancer research evolves, certain themes appear to be diminishing in prominence within the journal's recent publications. These waning scopes may reflect shifts in research priorities or advancements in understanding that render previous approaches less relevant.
  1. Traditional Chemotherapy Approaches:
    There is a noticeable decline in papers focusing on conventional chemotherapy regimens for liver cancer, as newer targeted therapies and immunotherapies gain traction and demonstrate better efficacy.
  2. Basic Science without Clinical Application:
    Research that solely delves into basic science without a clear translational application seems to be less prominent, indicating a shift towards studies that emphasize clinical relevance and applicability in patient care.
  3. Liver Cancer Surveillance Protocols:
    While surveillance remains crucial, the frequency of studies focused on traditional surveillance protocols has decreased, possibly due to increased emphasis on personalized and risk-based screening strategies.

Similar Journals

Cancer Reports

Connecting researchers and clinicians for impactful change.
Publisher: WILEYISSN: Frequency: 12 issues/year

Cancer Reports, published by WILEY, is an esteemed open-access journal dedicated to the field of oncology and cancer research. With a focus on disseminating impactful research findings since its transition to fully open access in 2021, Cancer Reports aims to facilitate knowledge sharing among researchers, clinicians, and healthcare professionals globally. The journal is positioned within the Q3 quartile for both Cancer Research and Oncology categories as of 2023, reflecting its commitment to quality and relevance in a competitive publishing landscape. With an ISSN of N/A and an E-ISSN of 2573-8348, the journal showcases studies across diverse aspects of cancer biology, treatment modalities, and patient care strategies. Located in the United Kingdom at 111 River St, Hoboken 07030-5774, NJ, Cancer Reports strives to contribute to the advancement of cancer research and improve health outcomes for patients worldwide, making it a pivotal platform for scholars and practitioners in the oncology community.

Current Problems in Cancer: Case Reports

Empowering cancer research with real-world case reports.
Publisher: ELSEVIERISSN: 2666-6219Frequency: 2 issues/year

Current Problems in Cancer: Case Reports is a prominent scholarly journal published by Elsevier, focusing on critical case reports within the field of oncology. Since its transition to Open Access in 2020, it has enhanced accessibility for researchers and healthcare professionals seeking to share and discuss unique clinical scenarios and insights that advance cancer treatment and patient care. Operating from the United States, this journal aims to address the important and often intricate challenges faced in oncology, facilitating a platform for knowledge exchange and the exploration of new perspectives in cancer management. Despite its current Q4 category ranking in the 2023 oncology category of Scopus with a rank of #359/404, its goal is to enrich the academic discourse by featuring diverse case reports and promoting evidence-based practices. As the journal evolves from 2021 to 2024, it seeks to impact the field by inviting researchers, professionals, and students to contribute their findings, ultimately fostering a collaborative environment for tackling the complexities of cancer.

Hepatic Oncology

Transforming Knowledge into Practice in Hepatic Oncology
Publisher: FUTURE MEDICINE LTDISSN: 2045-0923Frequency: 4 issues/year

Hepatic Oncology is a premier Open Access journal published by Future Medicine Ltd that specializes in the critical intersection of hepatology and oncology. With a focus on advancing knowledge in the diagnosis and treatment of liver cancers, the journal provides a platform for innovative research, reviews, and clinical perspectives that serve as a valuable resource for researchers, clinicians, and students alike. Established in 2016 and evolving over the years, Hepatic Oncology underscores its commitment to accessible scientific communication, having transitioned to open access in 2018 to reach a broader audience. The journal holds a Q4 quartile ranking in the fields of hepatology and oncology for 2023, reflecting its emerging influence and role in contemporary research. Through high-quality articles and a focus on real-world applications, Hepatic Oncology aims to bridge gaps in knowledge while fostering collaboration among professionals dedicated to enhancing patient care in hepatic malignancies.

Liver Cancer

Exploring innovative treatments and strategies for liver cancer.
Publisher: KARGERISSN: 2235-1795Frequency: 6 issues/year

Liver Cancer is a premier, peer-reviewed journal dedicated to the comprehensive study and advancement of knowledge surrounding liver neoplasms. Published by KARGER and headquartered in Switzerland, this journal has been an open-access platform since 2012, providing researchers with invaluable insights into the rapidly evolving field of hepatology and oncology. With an impressive impact factor that places it in the Q1 category for both Hepatology and Oncology in 2023, Liver Cancer stands out as a high-impact conduit for groundbreaking research, ranking #19 out of 404 in Medicine _ Oncology and #6 out of 82 in Medicine _ Hepatology according to Scopus. Researchers, practitioners, and students are encouraged to engage with the journal's content, which encompasses clinical studies, basic research, and reviews that contribute significantly to understanding liver cancer dynamics, diagnosis, and treatment strategies. This journal not only facilitates the dissemination of knowledge but also fosters collaboration in a well-established and impactful global scientific community.

Translational Oncology

Transforming Cancer Insights into Clinical Solutions
Publisher: ELSEVIER SCIENCE INCISSN: 1936-5233Frequency: 6 issues/year

Translational Oncology is a premier open access journal published by Elsevier Science Inc, dedicated to the rapidly evolving field of cancer research and oncology. Since its inception in 2008, the journal has been a vital platform for the dissemination of innovative research and findings that bridge the gap between laboratory discoveries and clinical applications. With an impressive impact factor and ranked Q2 in Cancer Research and Q1 in Oncology, it occupies a prominent position in the academic landscape, helping to shape the future of cancer therapeutics and patient care. The journal offers valuable insights across a diverse array of topics, including molecular biology, genetic factors in cancer, and innovative treatment strategies, ensuring relevance and engagement for its readership. As it converges toward 2024, Translational Oncology continues to attract a global audience of researchers, healthcare professionals, and students committed to advancing our understanding of cancer and enhancing clinical outcomes.

World Journal of Hepatology

Elevating the discourse on liver health and disease management.
Publisher: BAISHIDENG PUBLISHING GROUP INCISSN: 1948-5182Frequency: 12 issues/year

World Journal of Hepatology is a premier academic journal dedicated to advancing the field of hepatology. Published by BAISHIDENG PUBLISHING GROUP INC, this journal serves as a crucial platform for disseminating innovative research findings and critical reviews from around the globe. With its ISSN 1948-5182 and E-ISSN 1948-5182, the journal has established a notable presence since its inception in 2009, covering a wide range of topics relevant to liver diseases, including but not limited to hepatitis, liver cancer, and metabolic liver disorders. Currently ranked 41/82 in the field of hepatology by Scopus, representing the 50th percentile, it has achieved a Q3 quartile ranking in the 2023 category, underscoring its growing influence in the medical community. With a commitment to open access for its readership, the World Journal of Hepatology enriches the global discourse on liver health and disease management, making it an essential resource for researchers, clinicians, and students alike.

World Journal of Gastrointestinal Oncology

Illuminating the complexities of gastrointestinal cancer research.
Publisher: BAISHIDENG PUBLISHING GROUP INCISSN: 1948-5204Frequency: 12 issues/year

World Journal of Gastrointestinal Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a pivotal resource in the evolving fields of gastroenterology and oncology, particularly focused on the intricate relationship between gastrointestinal disorders and cancer. Established in 2014, the journal continues to publish influential research, boasting a commendable Q2 ranking in both the gastroenterology and oncology categories for 2023, which underscores its importance in these critical medical domains. With a diverse range of topics and studies, it serves as an essential platform for researchers, healthcare professionals, and students aiming to stay informed about the latest advancements and innovations in gastrointestinal oncology. Though currently not classified as open access, the journal's rigorous peer-review process ensures the dissemination of high-quality research that significantly contributes to clinical practice and patient care. Its positioning in the Scopus rankings also highlights its competitive standing within the scientific community, fostering discussions that are crucial for advancing both fields. Explore the latest insights and findings to enhance your understanding and contribute to the ongoing dialogue in gastrointestinal health and oncology.

Clinical Lung Cancer

Empowering clinicians with cutting-edge lung cancer studies.
Publisher: CIG MEDIA GROUP, LPISSN: 1525-7304Frequency: 6 issues/year

Clinical Lung Cancer is a prestigious journal published by CIG MEDIA GROUP, LP, dedicated to advancing the field of oncology and pulmonary medicine since its establishment in 2000. With an impressive impact factor and high ranking within its fields—achieving Q1 status in Oncology and Pulmonary and Respiratory Medicine in 2023—this journal serves as a vital resource for researchers, clinicians, and students alike. Covering a wide scope of topics related to lung cancer, Clinical Lung Cancer offers a platform for innovative studies, clinical trials, and comprehensive reviews that contribute to both theory and practice. While it operates on a subscription basis, the quality of content is reflected in its ranked status within the top quartile of cancer research journals. This journal plays a critical role in shaping the future of lung cancer research and treatment, making it an essential destination for those looking to stay at the forefront of the field.

World Journal of Clinical Oncology

Elevating Oncology Knowledge for Healthcare Professionals
Publisher: BAISHIDENG PUBLISHING GROUP INCISSN: 2218-4333Frequency: 12 issues/year

World Journal of Clinical Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a vital resource in the realm of oncology, providing a dedicated platform for the dissemination of cutting-edge research and clinical advancements. With an ISSN of 2218-4333, this journal facilitates a comprehensive exploration of modern oncology challenges and breakthroughs, targeting researchers, healthcare professionals, and students alike. Although it operates under the traditional subscription model, the impactful nature of its content is reflected in its notable ranking of 60 out of 334 in the category of Medicine _ Oncology, placing it in the 82nd percentile among peer publications. Covering significant topics in clinical oncology from 2014 to 2018, the journal has been instrumental in addressing evolving oncology practices and patient care innovations. By publishing high-quality studies, it remains an essential tool for advancing knowledge and fostering collaboration within the global oncology community.

Oncologie

Exploring innovative solutions in oncology.
Publisher: WALTER DE GRUYTER GMBHISSN: 1292-3818Frequency: 6 issues/year

Oncologie is a distinguished academic journal published by WALTER DE GRUYTER GMBH, focusing on the dynamic and vital field of oncology. Established in 1999 and continuously published until 2024, this journal provides a platform for high-quality research and advancements in cancer treatment, prevention, and diagnosis. With an ISSN of 1292-3818 and an E-ISSN of 1765-2839, it is indexed in various databases, contributing to its growing visibility. Although categorized in the Q3 quartile for oncology research as of 2023, Oncologie offers essential insights and fosters scholarly dialogue among researchers, professionals, and students interested in oncology. Its unique contributions aim to bridge the gap between theoretical frameworks and clinical applications, making it a valuable resource for those seeking to advance their knowledge and expertise in cancer research.